Category - Developments

Developments

Titan Pharma’s Probuphine now in use across Canada

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant for opioid use disorder is now being used in patients across Canada. Approved by Health Canada in April 2018, Probuphine is the only subdermal implant designed to...

April 15, 2019

Developments

Profound Medical analyst day illustrates strong case for adoption of TULSA-PRO

Analysts for Paradigm Capital and Canaccord Genuity in new reports said that Profound Medical’s (NASDAQ:PRFMF; TSX:PRN) inaugural analyst day illustrated a strong case for adoption of the company’s TULSA-PRO device for...

April 12, 2019

Developments

OPKO reports additional Phase 2 data for Type 2 diabetes and obesity candidate

OPKO Health (NASDAQ:OPK) reported additional results from its Phase 2 dose escalation trial of OPK-88003, a once-weekly oxyntomodulin for the treatment of Type 2 diabetes and obesity. OPK-88003 is a dual GLP-1/glucagon...

April 12, 2019

Developments

KemPharm completes pre-IND meeting for ADHA candidate

KemPharm (NASDAQ:KMPH) met with the FDA to discuss the NDA for KP415, its attention deficit hyperactivity disorder (ADHD) drug candidate. KP415 consists KemPharm’s prodrug of d-methylphenidate (d-MPH), co-formulated...

April 12, 2019

Developments

GlycoMimetics planning proof-of-concept trial for anti-tumor candidate

GlycoMimetics (NASDAQ:GLYC) plans to test GMI-1359, a dual function antagonist, in breast cancer patients whose tumors have spread to bone. GMI-1359 targets both E-selectin and CXCR4, which are involved in tumor...

April 12, 2019

Developments

Eiger presents positive Phase 2 results for hepatitis D candidate

Eiger BioPharmaceuticals (NASDAQ:EIGR) presented positive post-treatment results from its Phase 2 trial of lambda interferon monotherapy (LIMT) in patients with chronic hepatitis D virus (HDV). The study enrolled 33...

April 12, 2019

Developments

TRACON Pharma terminates Phase 3 TAPPAS trial in angiosarcoma

TRACON Pharmaceuticals (NASDAQ:TCON) terminated for futility its Phase 3 TAPPAS trial, evaluating TRC105 in combination with Votrient in patients with advanced or metastatic angiosarcoma, based on a recommendation of...

April 12, 2019

Developments

Hancock Jaffe implants four VenoValves in first-in-human study

Hancock Jaffe (NASDAQ:HJLI) has implanted VenoValves in four patients with severe, chronic venous insufficiency (CVI) as part of its first-in-human study of the device. CVI occurs when the valves in the veins of the leg...

April 11, 2019

Developments

Otonomy starts Phase 1/2 trial of OTO-313 for tinnitus

Otonomy (NASDAQ:OTIC) initiated a Phase 1/2 trial of OTO-313, a novel formulation of gacyclidine, for the treatment of tinnitus. Patients with tinnitus experience noise or ringing in their ears. Otonomy notes that some...

April 11, 2019

Developments

ContraVir Pharma to present CRV431 Phase 1 data at Intl Liver Congress

ContraVir Pharmaceuticals (NASDAQ:CTRV) will present a poster on a Phase 1 single ascending dose study of its drug candidate, CRV431, at the International Liver Congress, taking place in Vienna, Austria from April 10-to...

April 11, 2019

Category - Developments

Subscribe